Showing results (21-30 of 39) with videos related to
Sort By:
Pageof 4
Clinical Lung Cancer|May 28, 2026
High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase InhibitorsYunan Nie, Alyse Staley, Trista K Hinz, et al.Proceedings of the National Academy of Sciences of the United States of America|October 7, 2004
Paracellular Cl- permeability is regulated by WNK4 kinase: insight into normal physiology and hypertensionKristopher T Kahle, Gordon G Macgregor, Frederick H Wilson, et al.Nature Genetics|November 11, 2003
WNK4 regulates the balance between renal NaCl reabsorption and K+ secretionKristopher T Kahle, Frederick H Wilson, Qiang Leng, et al.Science (New York, N.Y.)|October 23, 2004
A cluster of metabolic defects caused by mutation in a mitochondrial tRNAFrederick H Wilson, Ali Hariri, Anita Farhi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK InhibitionLisa Hunihan, Dejian Zhao, Heather Lazowski, et al.Lung Cancer (Amsterdam, Netherlands)|November 30, 2024
The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutationsTejas Patil, Dexiang Gao, Alexander Watson, et al.Proceedings of the National Academy of Sciences of the United States of America|December 17, 2014
Genetic modifiers of EGFR dependence in non-small cell lung cancerTanaz Sharifnia, Victor Rusu, Federica Piccioni, et al.JTO Clinical and Research Reports|September 30, 2021
Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung CancersNoura J Choudhury, Jaime L Schneider, Tejas Patil, et al.JTO Clinical and Research Reports|February 16, 2024
The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLCTejas Patil, Alyse Staley, Yunan Nie, et al.Nature Communications|January 6, 2025
MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trialMrinal Gounder, Melissa Johnson, Rebecca S Heist, et al.Pageof 4